OEP News
Press Release 09 May. 2022
OEP introduces the latest long-acting injection approved for the treatment of schizophrenia in Europe and acquires Taiwan and Hong Kong distribution rights to expand psychiatry product portfolio
MORE
Press Release 31 Mar. 2022
OEP Enters Weight Loss Market. The latest mechanistically modified oral drug has been approved by TFDA for listing
MORE
Press Release 07 Mar. 2022
New hypolipidemic compound drug enters South Korea. Orient Pharma alliance with KUHNIL PHARMA to explore new markets
MORE
Explore OEP
About OEP
Built on understanding and meeting the real needs of people,
OEP is aim to become a benchmark enterprise in the Asia Pacific
Careers
Sincerely invite you to join OEP
Business Development
Continues to introduce a diverse range of innovative products and
expanding its overseas markets
Investors
Monthly Revenues 2022 April
CSR
OEP hopes to create a better society through continuous efforts and innovation
OEP Subsidiaries
Orient PHARMA, OP NanoPharma &
OEP Innovations
Overseas Business
To follow the trend of internationalization, Orient EuroPharma started to expand the foreign market in 1993 by establishing subsidiaries in Southeast Asia and moved into the Mainland China market with a complete marketing network.
